<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pura-dis" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pura-dis</book-part-id>
      <title-group>
        <title><italic toggle="yes">PURA</italic>-Related Neurodevelopmental Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reijnders</surname>
            <given-names>Margot RF</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff1"/>
          <email>margot.reijnders@radboudumc.nl</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leventer</surname>
            <given-names>Richard J</given-names>
          </name>
          <degrees>MBBS, BMedSci, PhD, FRACP</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff2"/>
          <email>richard.leventer@rch.org.au</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Bo Hoon</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff3"/>
          <email>bohoon_lee@urmc.rochester.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baralle</surname>
            <given-names>Diana</given-names>
          </name>
          <degrees>MBBS, MD, FRCP</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff4"/>
          <xref ref-type="aff" rid="pura-dis.Tc.aff5"/>
          <email>d.baralle@soton.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Selber</surname>
            <given-names>Paulo</given-names>
          </name>
          <degrees>MD, SBOT, FRACS</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff6"/>
          <email>pselberinfo@icloud.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Paciorkowski</surname>
            <given-names>Alex R</given-names>
          </name>
          <degrees>MD, FACMG</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff3"/>
          <email>alex_paciorkowski@urmc.rochester.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hunt</surname>
            <given-names>David</given-names>
          </name>
          <degrees>MBBS, PhD, MRCP</degrees>
          <xref ref-type="aff" rid="pura-dis.Tc.aff4"/>
          <email>david.hunt2@uhs.nhs.uk</email>
        </contrib>
      </contrib-group>
      <aff id="pura-dis.Tc.aff1">Department of Human Genetics<break/>Radboud Unversity Medical Center<break/>Nijmegen, The Netherlands</aff>
      <aff id="pura-dis.Tc.aff2">Department of Neurology<break/>Murdoch Children&#x02019;s Research Institute<break/>Department of Paediatrics<break/>University of Melbourne<break/>The Royal Children's Hospital Melbourne<break/>Victoria, Australia</aff>
      <aff id="pura-dis.Tc.aff3">Child Neurology<break/>University of Rochester Medical Center<break/>Rochester, New York</aff>
      <aff id="pura-dis.Tc.aff4">Wessex Clinical Genetics Service<break/>Princess Anne Hospital<break/>Southampton, United Kingdom</aff>
      <aff id="pura-dis.Tc.aff5">Human Development and Health<break/>Faculty of Medicine<break/>University of Southampton<break/>Southampton, United Kingdom</aff>
      <aff id="pura-dis.Tc.aff6">Department of Orthopaedics<break/>Royal Children&#x02019;s Hospital Melbourne<break/>Victoria, Australia</aff>
      <pub-history>
        <date date-type="created">
          <day>27</day>
          <month>4</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="phts" document-type="chapter">
<italic toggle="yes">PTEN</italic> Hamartoma Tumor Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pc" document-type="chapter">Pachyonychia Congenita</related-object>
      <abstract id="pura-dis.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">PURA</italic>-related neurodevelopmental disorders include <italic toggle="yes">PURA</italic> syndrome, caused by a heterozygous pathogenic sequence variant in <italic toggle="yes">PURA</italic>, and 5q31.3 deletion syndrome, caused by a genomic 5q31.3 deletion encompassing all or part of <italic toggle="yes">PURA.</italic>
<italic toggle="yes">PURA</italic>-related neurodevelopmental disorders are characterized by moderate to severe neurodevelopmental delay with absence of speech in most and lack of independent ambulation in many. Early-onset problems can include hypotonia, hypothermia, hypersomnolence, feeding difficulties, excessive hiccups, recurrent central and obstructive apneas, epileptic seizures, abnormal non-epileptic movements (dystonia, dyskinesia, and dysconjugate eye movements), and abnormal vision. Congenital heart defects, urogenital malformations, skeletal abnormalities, and endocrine disorders occur, but are less common.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder is established in a proband with either a heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant (90% of affected individuals) or a non-recurrent deletion of 5q31.3 that encompasses all or part of <italic toggle="yes">PURA</italic> (10%).</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Ongoing routine care by a multidisciplinary team. Treatment and/or therapy for developmental delays; neurologic findings (hypotonia, seizures, abnormal movements); feeding difficulties; apnea; visual impairment; and malformations of the heart, urogenital tract, and skeleton.</p>
          <p><italic toggle="yes">Surveillance</italic>: Long-term follow up to assess psychomotor development, seizures or suspected seizures, vision, feeding for dysphagia, and musculoskeletal complications (hip dysplasia and scoliosis).</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">PURA</italic>-related neurodevelopmental disorders, caused by either a heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant or a 5q31.3 deletion encompassing all or part of <italic toggle="yes">PURA</italic> are inherited in an autosomal dominant manner. In almost all probands with a <italic toggle="yes">PURA</italic> pathogenic sequence variant the sequence variant is <italic toggle="yes">de novo</italic>; to date, all reported 5q31.3 deletions have been <italic toggle="yes">de novo</italic>. For parents of an affected child, the risk to future pregnancies is presumed to be low, as a <italic toggle="yes">de novo</italic> genetic alteration involving <italic toggle="yes">PURA</italic> is most likely in the proband. However, parents of an affected child may wish to consider prenatal testing or preimplantation genetic diagnosis as risk may be greater than in the general population owing to the possibility of parental germline mosaicism (estimated empirically at &#x0003c;1%).</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pura-dis.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="pura-dis.Td" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_pura-dis.Td_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">PURA</italic>-Related Neurodevelopmental Disorders: Included Disorders</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_pura-dis.Td_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p><italic toggle="yes">PURA</italic> syndrome</p>
                    </list-item>
                    <list-item>
                      <p>5q31.3 deletion syndrome</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="pura-dis.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="pura-dis.Diagnosis">
        <title>Diagnosis</title>
        <p>No formal clinical diagnostic criteria have been published for <italic toggle="yes">PURA</italic>-related neurodevelopmental disorders, which comprise <italic toggle="yes">PURA</italic> syndrome (caused by a heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant) and 5q31.3 deletion syndrome (caused by a non-recurrent 5q31.3 deletion encompassing all or part of <italic toggle="yes">PURA</italic>).</p>
        <sec id="pura-dis.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">A PURA</italic>-related neurodevelopmental disorder <bold>should be suspected</bold> in infants and older individuals with the following clinical findings.</p>
          <p>
            <bold>Infants</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Hypotonia</p>
            </list-item>
            <list-item>
              <p>Neonatal hypoventilation</p>
            </list-item>
            <list-item>
              <p>Hypothermia</p>
            </list-item>
            <list-item>
              <p>Hypersomnolence</p>
            </list-item>
            <list-item>
              <p>Feeding difficulties, including gastroesophageal reflux disease (GERD)</p>
            </list-item>
          </list>
          <p>
            <bold>Older individuals</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Hypotonia</p>
            </list-item>
            <list-item>
              <p>Moderate-severe intellectual disability, including absent speech</p>
            </list-item>
            <list-item>
              <p>Seizures</p>
            </list-item>
            <list-item>
              <p>Abnormal non-epileptic movements (e.g., dystonia, dyskinesia, and dysconjugate eye movements)</p>
            </list-item>
          </list>
        </sec>
        <sec id="pura-dis.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder <bold>is established</bold> in a proband with one of the following genetic findings (see <xref ref-type="table" rid="pura-dis.T.molecular_genetic_testing_use">Table 1</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>A heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant (90% of affected individuals)</p>
            </list-item>
            <list-item>
              <p>Non-recurrent deletion of 5q31.3 that encompasses all or part of <italic toggle="yes">PURA</italic> (10%)</p>
            </list-item>
          </list>
          <p>Molecular genetic testing approaches can include a combination of <bold>genomic testing</bold> (chromosomal microarray analysis, comprehensive genome sequencing) and <bold>gene-targeted testing</bold> (multi-gene panel and single-gene testing).</p>
          <p>Gene-targeted testing requires the clinician to determine which specific gene(s) are likely involved, whereas genomic testing does not. Because the phenotypes of many genetic intellectual disability disorders overlap, most children with a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder are diagnosed by one of the following.</p>
          <sec id="pura-dis.Recommended_Testing">
            <title>Recommended Testing</title>
            <p><bold>A multi-gene panel</bold> which includes <italic toggle="yes">PURA</italic> and other genes of interest (see Differential Diagnosis). Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based analyses. For this disorder, a multi-gene panel that also includes copy number analysis is recommended (see <xref ref-type="table" rid="pura-dis.T.molecular_genetic_testing_use">Table 1</xref>).</p>
            <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            <p><bold>Chromosomal microarray analysis (CMA</bold>) to detect large, non-recurrent 5q31.3 deletions that include <italic toggle="yes">PURA</italic> which cannot readily be detected by sequence analysis of <italic toggle="yes">PURA</italic>.</p>
          </sec>
          <sec id="pura-dis.Testing_to_Consider">
            <title>Testing to Consider</title>
            <p><bold>Comprehensive genome sequencing</bold> (when available) includes exome sequencing and genome sequencing. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            <p>Note: Single-gene testing (sequence analysis of <italic toggle="yes">PURA,</italic> followed by gene-targeted deletion/duplication analysis) may be helpful in some circumstances &#x02013; for example, when clinical suspicion in a neonate is considerable and a rapid diagnosis would be beneficial.</p>
            <table-wrap id="pura-dis.T.molecular_genetic_testing_use" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in <italic toggle="yes">PURA</italic>-related Neurodevelopmental Disorders</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PURA</italic>
                    </td>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">71/79&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">CMA&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_pura-dis.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8/79&#x000a0;<sup>8</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="pura-dis.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="pura-dis" object-id="pura-dis.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="pura-dis.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="pura-dis.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="pura-dis.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="pura-dis.TF.1.4">
                  <label>4. </label>
                  <p>n=11 [<xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>], n=4 [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>], n=6 [<xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>], n=1 [<xref ref-type="bibr" rid="pura-dis.REF.okamoto.2017">Okamoto et al 2017</xref>], n=49 [Author, personal observation]</p>
                </fn>
                <fn id="pura-dis.TF.1.5">
                  <label>5. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="pura-dis.TF.1.6">
                  <label>6. </label>
                  <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
                </fn>
                <fn id="pura-dis.TF.1.7">
                  <label>7. </label>
                  <p>Chromosomal microarray analysis (CMA) using oligonucleotide arrays or SNP arrays. CMA designs in current clinical use target the 5q31.3 region.</p>
                </fn>
                <fn id="pura-dis.TF.1.8">
                  <label>8. </label>
                  <p>n=2 [<xref ref-type="bibr" rid="pura-dis.REF.shimojima.2011.732">Shimojima et al 2011</xref>], n=3 [<xref ref-type="bibr" rid="pura-dis.REF.hosoki.2012.1891">Hosoki et al 2012</xref>], n=2 [<xref ref-type="bibr" rid="pura-dis.REF.brown.2013.2604">Brown et al 2013</xref>], n=1 [<xref ref-type="bibr" rid="pura-dis.REF.bonaglia.2015.89">Bonaglia et al 2015</xref>]</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="pura-dis.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pura-dis.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">PURA</italic>-related neurodevelopmental disorders comprise <italic toggle="yes">PURA</italic> syndrome (caused by a heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant) and 5q31.3 deletion syndrome (caused by a non-recurrent 5q31.3 deletion encompassing all or part of <italic toggle="yes">PURA</italic>). <italic toggle="yes">PURA</italic>-related neurodevelopmental disorders are characterized by moderate to severe neurodevelopmental delay; most affected individuals are nonverbal, and many do not achieve independent ambulation.</p>
          <p>Early-onset problems are wide ranging and can include hypotonia, hypothermia, hypersomnolence, feeding difficulties, excessive hiccups, recurrent central and obstructive apneas, epileptic seizures, abnormal non-epileptic movements, and visual problems.</p>
          <p>Congenital heart defects, urogenital malformations, skeletal abnormalities, and endocrine disorders occur, but are less common [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; <xref ref-type="bibr" rid="pura-dis.REF.okamoto.2017">Okamoto et al 2017</xref>; Author, personal observation].</p>
          <p>The figures given for the following clinical features are based on observed frequencies in individuals with <italic toggle="yes">PURA</italic> syndrome. Individuals with 5q31.3 deletions encompassing <italic toggle="yes">PURA</italic> have not been included here as they have non-recurrent chromosomal deletions of varying sizes; thus, genetically, they represent a comparatively heterogeneous group.</p>
          <p><bold>Development.</bold> All 71 individuals with <italic toggle="yes">PURA</italic> syndrome reported to date have had moderate-to-severe neurodevelopmental delay.</p>
          <p>Speech is absent in most; however, the use of augmentative and alternative communication aids has proved beneficial in some children. Many children have relatively good receptive language skills and may follow simple instructions, despite having no overt expressive language.</p>
          <p>Motor development is delayed, but with variable severity. Some individuals never achieve independent ambulation. In those who do, the age ranges from 22 months to seven years. The gait of affected children is typically broad-based.</p>
          <p>Many individuals have poor fine-motor skills, which can hinder the use of some types of communication aids.</p>
          <p><bold>Neurologic.</bold> Severe hypotonia and hypersomnolence are common at birth.</p>
          <p>Epilepsy has been reported in at least 50% of the individuals (42/71) and usually starts with myoclonic jerks progressing to other seizure types including generalized tonic-clonic seizures, tonic seizures, and epileptic spasms. In some instances, the seizure disorder progresses to the Lennox-Gastaut syndrome.</p>
          <p>The age of seizure onset ranges between the neonatal period and 16 years, although most of those who develop epilepsy do so in the first five years, many in infancy.</p>
          <p>The seizures are often drug resistant.</p>
          <p>Non-epileptic movements that may be seen include dystonia, dyskinesia, and dysconjugate eye movements.</p>
          <p>Non-epileptic exaggerated startle response is present in several children.</p>
          <p>Nystagmus is present in 17/71 individuals.</p>
          <p>MRI findings include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Delayed myelination or nonspecific subtle white matter hyperintensities, which constitute the most frequently reported brain abnormalities (23/71)</p>
            </list-item>
            <list-item>
              <p>Excessive extra-axial fluid spaces (7/71)</p>
            </list-item>
            <list-item>
              <p>Volume loss of the corpus callosum (4/71)</p>
            </list-item>
            <list-item>
              <p>Cerebellar tonsillar ectopia (1/71)</p>
            </list-item>
            <list-item>
              <p>Possible cerebral atrophy (1/71)</p>
            </list-item>
            <list-item>
              <p>Absent septum pellucidum (1/71)</p>
            </list-item>
          </list>
          <p><bold>Ophthalmologic.</bold> Strabismus, Brown syndrome, and exophoria are the most frequently reported abnormalities (21/71).</p>
          <p>Early cortical visual impairment (7/71), hypermetropia (6/71), and optic nerve pallor (1/71) have also been reported.</p>
          <p><bold>Respiratory.</bold> Apnea and hypoventilation are present in more than 50% of affected individuals (42/71).</p>
          <p>For the majority of affected individuals, the episodes of apnea and hypoventilation resolve after the first year of life; however, in a minority, apnea may persist or recur during an acute respiratory illness.</p>
          <p>Aspiration pneumonia due to hypotonia and dysphagia has been reported.</p>
          <p><bold>Cardiovascular.</bold> Structural heart defects, present in a minority of affected individuals, include ventricular septal defect (3/71), persistent foramen ovale (2/71), persistent ductus arteriosus (1/71), pulmonic stenosis (1/71), atrial septal defect (1/71), bicuspid aortic valve (1/71), and aberrant left subclavian artery (1/71). However, it should be borne in mind that these figures may represent an underestimate (particularly of minor cardiac abnormalities that may not be manifesting obvious signs of disease) as not all individuals will have had an echocardiogram as a matter of course.</p>
          <p><bold>Gastrointestinal.</bold> A significant number of neonates have severe feeding difficulties and/or gastroesophageal reflux disease (GERD) (56/71).</p>
          <p>Dysphagia often persists throughout life. Drooling is common; however, the cause (either excessive salivation or oromotor dyspraxia/swallowing problems) requires further investigation.</p>
          <p>Constipation has been reported in the majority of individuals [<xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; Author, personal observation].</p>
          <p><bold>Urogenital.</bold> In four affected individuals, renal and genital defects including cryptorchidism (3/71), kidney stones (3/71), congenital hydronephrosis (2/71), prolapsed uterus (1/71), and urinary reflux (1/71) have been reported.</p>
          <p><bold>Skeletal.</bold> Scoliosis (13/71), hip dysplasia (11/71), and osteoporosis/osteopenia (7/71) are the most frequently reported skeletal abnormalities.</p>
          <p><bold>Endocrine.</bold> Anterior pituitary dysregulation may be within the spectrum of <italic toggle="yes">PURA</italic>-related neurodevelopmental disorders [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>] based on the following observations:</p>
          <list list-type="bullet">
            <list-item>
              <p>Disturbed levels of gonadotropins (2/71) and medical treatment for precocious puberty (3/71)</p>
            </list-item>
            <list-item>
              <p>A blunted cortisol response (2/71)</p>
            </list-item>
            <list-item>
              <p>Hypothyroidism (2/71)</p>
            </list-item>
            <list-item>
              <p>Elevated prolactin levels (1/71)</p>
            </list-item>
          </list>
          <p>Although low vitamin D levels (7/71) and anemia and/or low iron levels (4/71) have been reported, the true prevalence may be higher as vitamin D and iron levels are often not measured routinely and deficiency may not be obvious clinically.</p>
          <p>
            <bold>Other</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Neonatal hypothermia. Difficulties in regulating body temperature in the neonatal period have not yet been reported in the literature, but appear to occur frequently [Author, personal observation].</p>
            </list-item>
            <list-item>
              <p>Excessive hiccups in utero and in the neonatal period have been observed in a significant proportion of the individuals [Author, personal observation].</p>
            </list-item>
          </list>
        </sec>
        <sec id="pura-dis.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Current data suggest that <italic toggle="yes">PURA</italic> variants in the region encoding the PUR III repeat cause a more severe phenotype than variants in the regions that encode PUR I or PUR II repeats (see <xref ref-type="sec" rid="pura-dis.Molecular_Genetics">Molecular Genetics</xref>, <bold>Normal gene product</bold>). However, the functional effect at a molecular level is not yet clear and requires further investigation [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>].</p>
          <p><italic toggle="yes">PURA</italic>-related neurodevelopmental disorders encompass both <italic toggle="yes">PURA</italic> syndrome and the 5q31.3 deletion syndrome. It has been suggested that <italic toggle="yes">PURA</italic> haploinsufficiency contributes to the neurodevelopmental phenotype of individuals with a 5q31.3 deletion [<xref ref-type="bibr" rid="pura-dis.REF.brown.2013.2604">Brown et al 2013</xref>].</p>
          <p>The features of individuals with a 5q31.3 deletion that overlap with those of individuals with a <italic toggle="yes">PURA</italic> pathogenic variant include: neonatal hypotonia, feeding difficulties, and respiratory difficulties as well as severe intellectual disability and epilepsy [<xref ref-type="bibr" rid="pura-dis.REF.shimojima.2011.732">Shimojima et al 2011</xref>, <xref ref-type="bibr" rid="pura-dis.REF.hosoki.2012.1891">Hosoki et al 2012</xref>, <xref ref-type="bibr" rid="pura-dis.REF.brown.2013.2604">Brown et al 2013</xref>, <xref ref-type="bibr" rid="pura-dis.REF.bonaglia.2015.89">Bonaglia et al 2015</xref>].</p>
          <p>Of note, individuals with a deletion that also includes the neighboring gene <italic toggle="yes">NRG2</italic> &#x02013; as well as those with larger deletions that encompass multiple genes in addition to <italic toggle="yes">PURA</italic> and <italic toggle="yes">NRG2</italic> &#x02013; show a more severe phenotype (including distinct facial dysmorphisms) than individuals with an intragenic <italic toggle="yes">PURA</italic> pathogenic variant. It has been suggested that deletion of <italic toggle="yes">NRG2</italic> contributes to the more severe phenotype observed in individuals with a large 5q31.3 deletion [<xref ref-type="bibr" rid="pura-dis.REF.brown.2013.2604">Brown et al 2013</xref>].</p>
        </sec>
        <sec id="pura-dis.Penetrance">
          <title>Penetrance</title>
          <p>To the authors&#x02019; knowledge, the penetrance of all intragenic <italic toggle="yes">PURA</italic> pathogenic variants and 5q31.3 deletions encompassing <italic toggle="yes">PURA</italic> is complete.</p>
        </sec>
        <sec id="pura-dis.Nomenclature">
          <title>Nomenclature</title>
          <p>The OMIM designation for <italic toggle="yes">PURA</italic>-related neurodevelopmental disorders - &#x0201c;mental retardation, autosomal dominant 31&#x0201d; (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616158">616158</ext-link>) - is no longer in use.</p>
        </sec>
        <sec id="pura-dis.Prevalence">
          <title>Prevalence</title>
          <p>To date, 71 individuals are known to have <italic toggle="yes">PURA</italic> syndrome [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; <xref ref-type="bibr" rid="pura-dis.REF.okamoto.2017">Okamoto et al 2017</xref>; Author, personal observation]. Eight individuals with the 5q31.3 deletion syndrome have been reported.</p>
          <p>Based on the study of <xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al [2014]</xref>, the estimated frequency of <italic toggle="yes">PURA</italic> syndrome as a cause of intellectual disability is 3:1,133 (0.3%).</p>
          <p><xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al [2014]</xref> and <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al [2015]</xref> estimated a higher frequency (0.5%) based on their cohorts of 11:2,117 and 6:1,098, respectively.</p>
        </sec>
      </sec>
      <sec id="pura-dis.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">PURA</italic>.</p>
      </sec>
      <sec id="pura-dis.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Disorders in the differential diagnosis of <italic toggle="yes">PURA</italic>-related neurodevelopmental disorders are:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="ondine" document-type="chapter">Congenital central hypoventilation syndrome</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="pws" document-type="chapter">Prader-Willi syndrome</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Lower extremity-predominant autosomal dominant spinal muscular atrophy 1 (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/158600">158600</ext-link>) / distal autosomal recessive spinal muscular atrophy 1 (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/604320">604320</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Myotonic dystrophy in the newborn (see <related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">Myotonic Dystrophy Type 1</related-object>)</p>
          </list-item>
          <list-item>
            <p>Neurotransmitter disorder [<xref ref-type="bibr" rid="pura-dis.REF.pearl.2007.606">Pearl et al 2007</xref>]</p>
          </list-item>
          <list-item>
            <p>Rett syndrome (see <related-object link-type="booklink" source-id="gene" document-id="rett" document-type="chapter"><italic toggle="yes">MECP2</italic>-Related Disorders</related-object>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="pitt-hopkins" document-type="chapter">Pitt-Hopkins syndrome</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="angelman" document-type="chapter">Angelman syndrome</related-object>
            </p>
          </list-item>
        </list>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.omim.org/phenotypicSeries/PS156200"><underline>Mental retardation, autosomal dominant: OMIM Phenotypic Series</underline></ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="pura-dis.Management">
        <title>Management</title>
        <sec id="pura-dis.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder, the following evaluations are recommended.</p>
          <table-wrap id="pura-dis.T.recommended_evaluations_follo" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Recommended Evaluations Following Initial Diagnosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Affected System</th>
                  <th id="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Evaluation</th>
                  <th id="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">Comment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Cognitive</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Developmental assessment</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Neurologic</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Neurologic evaluation</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Brain MRI</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Indicated in a child w/a <italic toggle="yes">PURA-</italic>related neurodevelopmental disorder w/seizures and/or hypoventilation and/or abnormal vision or eye movements who has not previously had a brain MRI</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" colspan="1" align="left" scope="row" rowspan="1">EEG and video EEG</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">If seizures are suspected</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Eyes</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Ophthalmology examination</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Electrodiagnostic tests may be indicated in some cases.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Cardiovascular</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Consider echocardiogram</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Respiratory</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Assessment of pulmonary function</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">As needed</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Gastrointestinal</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Feeding assessment w/analysis of swallowing &#x00026; evaluation for possible aspiration</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">As needed</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Assessment for constipation</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Genitourinary</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consider ultrasound of the urinary tract</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Musculoskeletal</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Appropriate radiographs</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If hip dysplasia and/or scoliosis is suspected</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Endocrine</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Assessment of serum vitamin D levels</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Assessment of bone density</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If osteoporosis or osteopenia is suspected</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Evaluation of anterior pituitary hormones</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If necessary</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Miscellaneous/other</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consultation w/a clinical geneticist and/or genetic counselor</td>
                  <td headers="hd_h_pura-dis.T.recommended_evaluations_follo_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="pura-dis.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Individuals often benefit when management is provided by a multidisciplinary team including relevant specialists, which may include, but is not limited to, a pediatrician, clinical geneticist, child neurologist, pulmonologist, ophthalmologist, orthopedic surgeon, physiotherapist, occupational therapist, and speech and language therapist.</p>
          <table-wrap id="pura-dis.T.treatment_of_manifestations_i" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Treatment of Manifestations in Individuals with <italic toggle="yes">PURA</italic>-Related Neurodevelopmental Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Manifestation</th>
                  <th id="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Treatment</th>
                  <th id="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">Considerations/Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cognitive/developmental delay</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See <xref ref-type="sec" rid="pura-dis.Global_Developmental_Disability">Global Developmental Disability/ Intellectual Disability Educational Issues</xref>.</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Seizures</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Management by a neurologist</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">May include video EEG monitoring to help distinguish epileptic from non-epileptic events (e.g., dystonia, dyskinesia, dysconjugate eye movements)</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Vision deficits</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Correction of refractive errors; vision support; standard treatment for strabismus &#x00026; exophoria</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Hypoventilation</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Supplementary oxygen (at night) &#x00026; rarely tracheostomy</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Ambulatory peripheral saturation monitoring may be required.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" colspan="1" align="left" scope="col" rowspan="1">Some infants require short periods of intubation &#x00026; mechanical ventilation, particularly during acute illness.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Congenital heart defect</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Management as per current practice for the specific congenital heart defect</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Frequent aspiration (or high risk of aspiration)</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">A percutaneous endoscopic gastrostomy tube may be considered.</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">GERD</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Medical management; consideration of Nissen fundoplication if medical treatment is not sufficient</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Constipation</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Routine management</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Referral to a gastroenterologist may be required in severe cases.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Congenital urogenital defect</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Management as per current practice for the specific urogenital defect</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Scoliosis</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Standard management</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Progressive neuropathic scoliosis may require spinal fusion.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Osteoporosis/osteopenia</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Standard management</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Instability in standing position</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ankle foot orthoses (AFO) may improve stability, allowing for better standing &#x00026; transferring ability.</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Neuropathic hip dysplasia, progressive subluxation, &#x00026; dislocation</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consideration of hip reconstructions w/varus derotational proximal femoral osteotomies</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Generalized joint laxity &#x00026; continued inability to walk may cause relapsing hip subluxation even after previous femoral osteotomies.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Vitamin D deficiency</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Vitamin D supplementation</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Anterior pituitary hormone deficiencies</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Standard treatment as directed by an endocrinologist</td>
                  <td headers="hd_h_pura-dis.T.treatment_of_manifestations_i_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>GERD = gastroesophageal reflux disease</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The following information represents typical management recommendations for individuals with developmental delay/intellectual disability in the United States; standard recommendations may vary from country to country.</p>
          <sec id="pura-dis.Global_Developmental_Disability">
            <title>Global Developmental Disability/ Intellectual Disability Educational Issues</title>
            <p><bold>For ages 0-3 years.</bold> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the United States, early intervention is a nationwide, federally funded program available in all states.</p>
            <p><bold>For ages 3-5 years.</bold> In the United States, developmental preschool through the local public school district is recommended. An evaluation will occur before placement to determine needed services and therapies and will be subsequently written into an individualized education plan (IEP).</p>
            <p>
              <bold>For ages 5-21 years</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>In the United States, an IEP should be developed by the local public school district based on each individual&#x02019;s level of function. Affected children are permitted to remain in the public school district until age 21.</p>
              </list-item>
              <list-item>
                <p>Discussion about transition plans including financial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</p>
              </list-item>
            </list>
            <p><bold>For all ages.</bold> Consultation with a developmental pediatrician is recommended to ensure that appropriate community, state, and educational agencies are involved and to support parents in maximizing quality of life. Some issues to consider:</p>
            <list list-type="bullet">
              <list-item>
                <p>Private supportive therapies based on the affected individual&#x02019;s needs. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p>
              </list-item>
              <list-item>
                <p>In the United States, enrollment in DDA (Developmental Disabilities Administration) is recommended. DDA is a public agency that provides services and supports to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</p>
              </list-item>
              <list-item>
                <p>In the United States, families with limited income and resources may also qualify for supplemental security income for their child with a disability.</p>
              </list-item>
            </list>
          </sec>
          <sec id="pura-dis.Motor_Dysfunction">
            <title>Motor Dysfunction</title>
            <p>
              <bold>Gross motor dysfunction</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., scoliosis, hip dislocation).</p>
              </list-item>
              <list-item>
                <p>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</p>
              </list-item>
              <list-item>
                <p>For muscle tone abnormalities including dystonia, consider involving appropriate specialists to aid in management of medications or orthopedic procedures.</p>
              </list-item>
            </list>
            <p><bold>Fine motor dysfunction.</bold> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function (e.g., feeding, grooming, dressing).</p>
            <p><bold>Oral motor dysfunction.</bold> Assuming that the individual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended for affected individuals who have difficulty feeding due to poor oral motor control.</p>
            <p><bold>Communication issues.</bold> Consider alternative means of communication for individuals who have expressive language difficulties, such as an Augmentative and Alternative Communication (AAC) evaluation.</p>
          </sec>
        </sec>
        <sec id="pura-dis.Surveillance">
          <title>Surveillance</title>
          <table-wrap id="pura-dis.T.recommended_surveillance_for" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Recommended Surveillance for Individuals with <italic toggle="yes">PURA</italic>-Related Neurodevelopmental Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Affected System</th>
                  <th id="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Evaluation</th>
                  <th id="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">Frequency/Comment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Cognitive</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Monitoring by developmental pediatrics</td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Long-term</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Neurologic</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">EEG &#x00026; video EEG monitoring</td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If seizures are suspected</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Eyes</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ophthalmologic &#x00026; vision evaluations</td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Routine</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Gastrointestinal</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Monitoring for dysphagia &#x00026; constipation</td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Routine</td>
                </tr>
                <tr>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Musculoskeletal</bold>
                  </td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Monitoring for musculoskeletal complications including hip dysplasia &#x00026; scoliosis</td>
                  <td headers="hd_h_pura-dis.T.recommended_surveillance_for_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Routine</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="pura-dis.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="pura-dis.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pura-dis.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pura-dis.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pura-dis.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">PURA</italic>-related neurodevelopmental disorders, caused by either a heterozygous <italic toggle="yes">PURA</italic> pathogenic sequence variant (<italic toggle="yes">PURA</italic> syndrome) or a 5q31.3 deletion encompassing all or part of <italic toggle="yes">PURA</italic> (5q31.3 deletion syndrome), are inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="pura-dis.Risk_to_Family_Members__PURA_Pa">
          <title>Risk to Family Members &#x02013; <italic toggle="yes">PURA</italic> Pathogenic Sequence Variant</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In almost all probands with a <italic toggle="yes">PURA</italic> pathogenic sequence variant the sequence variant is <italic toggle="yes">de novo</italic>.</p>
            </list-item>
            <list-item>
              <p>The exception is a child who was found to have inherited a <italic toggle="yes">PURA</italic> pathogenic sequence variant from her unaffected father, who had low-level mosaicism [Author, personal observation].</p>
            </list-item>
            <list-item>
              <p>Evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant by molecular genetic testing is recommended.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">PURA</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, the variant is most likely <italic toggle="yes">de novo</italic>; however, parental germline mosaicism is also a possibility.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the parents.</p>
            </list-item>
            <list-item>
              <p>Because almost all <italic toggle="yes">PURA</italic> pathogenic sequence variants reported to date have been <italic toggle="yes">de novo</italic>, the risk to sibs appears to be low (&#x0003c;1%), but greater than that of the general population because of the possibility of parental germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> To date, very few adults have been identified with a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder. None has had children. However, the theoretic risk to offspring of an affected individual is 50%.</p>
        </sec>
        <sec id="pura-dis.Risk_to_Family_Members__5q31_3">
          <title>Risk to Family Members &#x02013; 5q31.3 Deletion Encompassing All or Part of <italic toggle="yes">PURA</italic></title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>To date, all reported 5q31.3 deletions have been <italic toggle="yes">de novo</italic>.</p>
            </list-item>
            <list-item>
              <p>Evaluation of the parents by genomic testing that will detect the 5q31.3 deletion identified in the proband is recommended. It is also important to exclude a balanced chromosome rearrangement that may have predisposed to a deletion encompassing 5q31.3 in the proband.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the 5q31.3 deletion found in the proband is not identified in one of the parents, the risk to sibs is presumed to be low (&#x0003c;1%) but greater than that of the general population because of the theoretic possibility of parental germline mosaicism.</p>
            </list-item>
            <list-item>
              <p>If a predisposing balanced chromosome rearrangement is identified in a parent, genetic counseling is important as there may be a significant risk to the sibs of the proband.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> To date, very few adults have been identified with a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder. None has had children. However, the theoretic risk to offspring of an affected individual is 50%.</p>
        </sec>
        <sec id="pura-dis.Other_Family_Members">
          <title>Other Family Members</title>
          <p>Given that all probands with a <italic toggle="yes">PURA</italic>-related neurodevelopmental disorder reported to date have had a genetic alteration that is either <italic toggle="yes">de novo</italic> or inherited from a parent who has low-level mosaicism [Author, personal observation], the risk to other family members is presumed to be low.</p>
        </sec>
        <sec id="pura-dis.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to parents of affected individuals.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pura-dis.Prenatal_Testing_and_Preimplant">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Risk to future pregnancies is presumed to be low as the familial proband most likely has a <italic toggle="yes">de novo</italic> genetic alteration involving <italic toggle="yes">PURA</italic>. However, couples may wish to consider prenatal testing or preimplantation genetic diagnosis as their risk may be greater than in the general population because of the possibility of parental germline mosaicism.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="pura-dis.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pura-dis.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The <italic toggle="yes">PURA</italic> transcript <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005859.4">NM_005859.4</ext-link> has 5304 nucleotides, a single exon, and a coding sequence of 969 nucleotides.</p>
        <p><bold>Pathogenic variants.</bold> To date, 61 different <italic toggle="yes">de novo</italic>
<italic toggle="yes">PURA</italic> intragenic sequence variants are known, which include missense, nonsense, frameshift variants, and in-frame deletions [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; <xref ref-type="bibr" rid="pura-dis.REF.okamoto.2017">Okamoto et al 2017</xref>; Author, personal observation].</p>
        <p>All missense variants occur in regions encoding one of the three PUR repeats (see <bold>Normal gene product</bold>), while truncating pathogenic variants occur throughout the gene [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; <xref ref-type="bibr" rid="pura-dis.REF.okamoto.2017">Okamoto et al 2017</xref>; Author, personal observation].</p>
        <p><xref ref-type="table" rid="pura-dis.T.recommended_evaluations_follo">Table 2</xref> shows five recurrent pathogenic variants: c.697_699delTTC (7 individuals), c.289A&#x0003e;G (2 individuals), c.812_814delTCT (2 individuals), c.734G&#x0003e;C (2 individuals) and c.596G&#x0003e;C (2 individuals) [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>; <xref ref-type="bibr" rid="pura-dis.REF.tanaka.2015.a000356">Tanaka et al 2015</xref>; Author, personal observation].</p>
        <table-wrap id="pura-dis.T.pura_pathogenic_variants_disc" orientation="portrait" position="anchor">
          <label>Table 5. </label>
          <caption>
            <p><italic toggle="yes">PURA</italic> Pathogenic Variants Discussed in This GeneReview</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.289A&#x0003e;G</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Lys97Glu</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005859.4">NM_005859.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_005850.1">NP_005850.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.596G&#x0003e;C</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg199Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.697_699delTTC</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe233del</td>
              </tr>
              <tr>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.734G&#x0003e;C</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg245Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.812_814delTCT</td>
                <td headers="hd_h_pura-dis.T.pura_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe271del</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Relationship to 5q31.3 deletion syndrome.</bold>
<italic toggle="yes">PURA</italic> is one of three genes located within the critical deleted region associated with the 5q31.3 deletion syndrome [<xref ref-type="bibr" rid="pura-dis.REF.brown.2013.2604">Brown et al 2013</xref>]. The smallest microdeletion encompassing <italic toggle="yes">PURA</italic> has been reported by <xref ref-type="bibr" rid="pura-dis.REF.bonaglia.2015.89">Bonaglia et al [2015]</xref>.</p>
        <p><bold>Normal gene product.</bold> The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005859.4">NM_005859.4</ext-link> transcript encodes a highly conserved 322-amino acid protein, known as purine-rich element-binding protein A (Pur-alpha) [<xref ref-type="bibr" rid="pura-dis.REF.lalani.2014.579">Lalani et al 2014</xref>]. Pur-alpha is a multifunctional protein that has an important role in normal postnatal brain development in animal models [<xref ref-type="bibr" rid="pura-dis.REF.khalili.2003.6857">Khalili et al 2003</xref>, <xref ref-type="bibr" rid="pura-dis.REF.hokkanen.2012.473">Hokkanen et al 2012</xref>]. PUR-alpha is a sequence-specific, DNA-/RNA-binding protein with an important role in DNA replication, DNA transcription, mRNA trafficking, and unwindase activity [<xref ref-type="bibr" rid="pura-dis.REF.white.2009.1">White et al 2009</xref>, <xref ref-type="bibr" rid="pura-dis.REF.weber.2016.5">Weber et al 2016</xref>]. The functionality of Pur-alpha is dependent on three PUR repeat motifs: PUR I, PUR II, and PUR III [<xref ref-type="bibr" rid="pura-dis.REF.graebsch.2009.18521">Graebsch et al 2009</xref>, <xref ref-type="bibr" rid="pura-dis.REF.weber.2016.5">Weber et al 2016</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Effects of the pathogenic variants at functional levels are not yet clear, but such variants presumably cause functional haploinsufficiency of the protein [<xref ref-type="bibr" rid="pura-dis.REF.hunt.2014.806">Hunt et al 2014</xref>].</p>
      </sec>
      <sec id="pura-dis.References">
        <title>References</title>
        <ref-list id="pura-dis.References.reflist0">
          <ref id="pura-dis.REF.bonaglia.2015.89">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bonaglia</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Zanotta</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Giorda</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>D&#x02019;Angelo</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Zucca</surname>
                  <given-names>C</given-names>
                </name>
              </person-group>
              <article-title>Long-term follow-up of a patient with 5q31.3 microdeletion syndrome and the smallest de novo 5q31.2q31.3 deletion involving PURA.</article-title>
              <source>Mol Cytogenet</source>
              <year>2015</year>
              <volume>8</volume>
              <fpage>89</fpage>
              <pub-id pub-id-type="pmid">26582469</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.brown.2013.2604">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Burgess</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Forbes</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>McGillivray</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Kornberg</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Mandelstam</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Starl</surname>
                  <given-names>Z.</given-names>
                </name>
              </person-group>
              <article-title>5q31.3 Microdeletion syndrome: clinical and molecular characterization of two further cases.</article-title>
              <source>Am J Med Genet A</source>
              <year>2013</year>
              <volume>161A</volume>
              <fpage>2604</fpage>
              <lpage>8</lpage>
              <pub-id pub-id-type="pmid">23950017</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.graebsch.2009.18521">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Graebsch</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Roche</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Niessing</surname>
                  <given-names>D.</given-names>
                </name>
              </person-group>
              <article-title>X-ray structure of Pur-alpha reveals a Whirly-like fold and an unusual nucleic-acid binding surface.</article-title>
              <source>Proc Natl Acad Sci U S A</source>
              <year>2009</year>
              <volume>106</volume>
              <fpage>18521</fpage>
              <lpage>6</lpage>
              <pub-id pub-id-type="pmid">19846792</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.hokkanen.2012.473">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hokkanen</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Feldmann</surname>
                  <given-names>HM</given-names>
                </name>
                <name name-style="western">
                  <surname>Ding</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>CK</given-names>
                </name>
                <name name-style="western">
                  <surname>Bojarski</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Renner-M&#x000fc;ller</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Sch&#x000fc;ller</surname>
                  <given-names>U</given-names>
                </name>
                <name name-style="western">
                  <surname>Kretzschmar</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Wolf</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Herms</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Lack of Pur-alpha alters postnatal brain development and causes megalencephaly.</article-title>
              <source>Hum Mol Genet</source>
              <year>2012</year>
              <volume>21</volume>
              <fpage>473</fpage>
              <lpage>84</lpage>
              <pub-id pub-id-type="pmid">22010047</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.hosoki.2012.1891">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hosoki</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Ohta</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Natsume</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Imai</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Okumura</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Matsui</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Harda</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bacino</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Scaglia</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>JY</given-names>
                </name>
                <name name-style="western">
                  <surname>Niikawa</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Saitoh</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Clinical phenotype and candidate genes for the 5q31.3 microdeletion syndrome.</article-title>
              <source>Am J Med Genet A</source>
              <year>2012</year>
              <volume>158A</volume>
              <fpage>1891</fpage>
              <lpage>6</lpage>
              <pub-id pub-id-type="pmid">22711443</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.hunt.2014.806">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hunt</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Leventer</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Simons</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Taft</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Swoboda</surname>
                  <given-names>KJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Gawne-Cain</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Study</surname>
                  <given-names>DDD</given-names>
                </name>
                <name name-style="western">
                  <surname>Magee</surname>
                  <given-names>AC</given-names>
                </name>
                <name name-style="western">
                  <surname>Turnpenny</surname>
                  <given-names>PD</given-names>
                </name>
                <name name-style="western">
                  <surname>Baralle</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability.</article-title>
              <source>J Med Genet</source>
              <year>2014</year>
              <volume>51</volume>
              <fpage>806</fpage>
              <lpage>13</lpage>
              <pub-id pub-id-type="pmid">25342064</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.khalili.2003.6857">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Khalili</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Del Valle</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Muralidharan</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Gault</surname>
                  <given-names>WJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Darbinian</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Otte</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Meier</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>EM</given-names>
                </name>
                <name name-style="western">
                  <surname>Daniel</surname>
                  <given-names>DC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kinoshita</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Amini</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse.</article-title>
              <source>Mol Cell Biol</source>
              <year>2003</year>
              <volume>23</volume>
              <fpage>6857</fpage>
              <lpage>75</lpage>
              <pub-id pub-id-type="pmid">12972605</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.lalani.2014.579">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lalani</surname>
                  <given-names>SR</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Schaaf</surname>
                  <given-names>CP</given-names>
                </name>
                <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>CW</given-names>
                </name>
                <name name-style="western">
                  <surname>Magoulas</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Tsai</surname>
                  <given-names>AC</given-names>
                </name>
                <name name-style="western">
                  <surname>El-Gharbawy</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Wierenga</surname>
                  <given-names>KJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bartholomew</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Fong</surname>
                  <given-names>CT</given-names>
                </name>
                <name name-style="western">
                  <surname>Barbaro-Dieber</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Kukolich</surname>
                  <given-names>MK</given-names>
                </name>
                <name name-style="western">
                  <surname>Burrage</surname>
                  <given-names>LC</given-names>
                </name>
                <name name-style="western">
                  <surname>Austin</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Keller</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Pastore</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Fernandez</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Lotze</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Wilfong</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Purcarin</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhu</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Craigen</surname>
                  <given-names>WJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Mcguire</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Jain</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Cooney</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Azamian</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bainbridge</surname>
                  <given-names>MN</given-names>
                </name>
                <name name-style="western">
                  <surname>Muzny</surname>
                  <given-names>DM</given-names>
                </name>
                <name name-style="western">
                  <surname>Boerwinkle</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Person</surname>
                  <given-names>RE</given-names>
                </name>
                <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Eng</surname>
                  <given-names>CM</given-names>
                </name>
                <name name-style="western">
                  <surname>Lupski</surname>
                  <given-names>JR</given-names>
                </name>
                <name name-style="western">
                  <surname>Gibbs</surname>
                  <given-names>RA</given-names>
                </name>
                <name name-style="western">
                  <surname>Beaudet</surname>
                  <given-names>AL</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Xia</surname>
                  <given-names>F</given-names>
                </name>
              </person-group>
              <article-title>Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome.</article-title>
              <source>Am J Hum Genet</source>
              <year>2014</year>
              <volume>95</volume>
              <fpage>579</fpage>
              <lpage>83</lpage>
              <pub-id pub-id-type="pmid">25439098</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.okamoto.2017">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Okamoto</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Nakao</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Niihori</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Aoki</surname>
                  <given-names>Y.</given-names>
                </name>
              </person-group>
              <article-title>A patient with a novel purine-rich element binding protein A (PURA) mutation.</article-title>
              <source>Congenit Anom (Kyoto)</source>
              <year>2017</year>
              <month>Feb</month>
              <day>6</day>
              <comment/>
              <pub-id pub-id-type="doi">10.1111/cga.12214</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.pearl.2007.606">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pearl</surname>
                  <given-names>PL</given-names>
                </name>
                <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>Trzcinski</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Sokohl</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>The pediatric neurotransmitter disorders.</article-title>
              <source>J Child Neurol</source>
              <year>2007</year>
              <volume>22</volume>
              <fpage>606</fpage>
              <lpage>16</lpage>
              <pub-id pub-id-type="pmid">17690069</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.shimojima.2011.732">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shimojima</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Isidor</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Le Caignec</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Kondo</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Sakata</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Ohno</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamamoto</surname>
                  <given-names>T.</given-names>
                </name>
              </person-group>
              <article-title>A new microdeletion syndrome of 5q31.3 characterized by severe developmental delays, distinctive facial features, and delayed myelinisation.</article-title>
              <source>Am J Med Genet A</source>
              <year>2011</year>
              <volume>155A</volume>
              <fpage>732</fpage>
              <lpage>6</lpage>
              <pub-id pub-id-type="pmid">21594995</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.tanaka.2015.a000356">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tanaka</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bai</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Cho</surname>
                  <given-names>MT</given-names>
                </name>
                <name name-style="western">
                  <surname>Anyane-Yeboa</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Ahimaz</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>AL</given-names>
                </name>
                <name name-style="western">
                  <surname>Kendall</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Hay</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Moss</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Nardini</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bauer</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Retterer</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Juusola</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>WK</given-names>
                </name>
              </person-group>
              <article-title>De novo mutations in PURA are associated with hypotonia and developmental delay.</article-title>
              <source>Cold Spring Harb Mol Case Stud.</source>
              <year>2015</year>
              <volume>1</volume>
              <fpage>a000356</fpage>
              <pub-id pub-id-type="pmid">27148565</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.weber.2016.5">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Weber</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Bao</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Hartlm&#x000fc;ller</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Windhager</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Janowski</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Madl</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Jin</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Niessing</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Structural basis of nucleic-acid recognition and double-strand unwinding by the essential neuronal protein Pur-alpha.</article-title>
              <source>Elife.</source>
              <year>2016</year>
              <month>Jan</month>
              <day>8</day>
              <fpage>5</fpage>
              <pub-id pub-id-type="pmid">26744780</pub-id>
            </element-citation>
          </ref>
          <ref id="pura-dis.REF.white.2009.1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>White</surname>
                  <given-names>MK</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>EM</given-names>
                </name>
                <name name-style="western">
                  <surname>Khalili</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Multiple roles for Puralpha in cellular and viral regulation.</article-title>
              <source>Cell Cycle.</source>
              <year>2009</year>
              <volume>8</volume>
              <fpage>1</fpage>
              <lpage>7</lpage>
              <pub-id pub-id-type="pmid">19182532</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="pura-dis.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pura-dis.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>27 April 2017 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>13 May 2016 (dh) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
